{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T06:40:08Z","timestamp":1732257608630,"version":"3.28.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"23","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Secondary to the risk of antipsychotic-induced acute dystonia, prophylactic use of benztropine is occasionally warranted but is recommended for no longer than 7 days after initiating an antipsychotic, correlating to the period of highest dystonia risk. Despite the associated increased anticholinergic burden, many clinicians continue to order benztropine for periods exceeding the recommended prophylactic duration. We investigated the reduction of benztropine use duration subsequent to implementation of truncated electronic entry orders to improve benztropine prescribing within an acute psychiatric facility.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were collected for psychiatric inpatients admitted between January and June 2020 who were prescribed scheduled benztropine. In a quality improvement initiative implemented in April 2022, electronic orders for benztropine were modified from a 180-day to a 7-day duration, with subsequent postintervention data collection. The primary outcomes included a change in the duration of benztropine use for any indication in the hospital, and a change in the percentage of patients meeting predetermined \u201cunnecessary use\u201d criteria. Secondary analyses included the percentage of patients with discharge prescriptions for scheduled benztropine (either for prophylaxis or for other indications) in the pre- and postintervention periods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>73 pre- and 77 postintervention individual patients\/encounters were included. Following the intervention, in-hospital duration of benztropine use for any indication decreased from a median of 14 days to a median of 7.5 days (P &amp;lt; 0.05), and appropriate use increased by 92.9%. The percentage of patients with prescriptions for scheduled benztropine decreased from 67.1% in the preintervention group to 29.9% in the postintervention group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Decreased benztropine use duration, by means of truncated order entry sentences, during inpatient psychiatric admissions, appears feasible regardless of dual antipsychotic or first-generation antipsychotic use, and may reduce the rates of benztropine prescriptions written for discharge.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae196","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T15:48:04Z","timestamp":1721231284000},"page":"e742-e750","source":"Crossref","is-referenced-by-count":0,"title":["Reduction of benztropine use duration in acute psychiatry: A quality improvement initiative"],"prefix":"10.1093","volume":"81","author":[{"given":"Whitney","family":"Seals","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Alabama at Birmingham Medical Center , Birmingham, AL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Pat","family":"Holder","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Alabama at Birmingham Medical Center , Birmingham, AL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shea","family":"Polancich","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, School of Nursing , Birmingham, AL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"James Edward","family":"Bryant","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine , Birmingham, AL"},{"name":"Department of Psychiatry, University of Alabama at Birmingham Medical Center , Birmingham, AL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badari","family":"Birur","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine , Birmingham, AL"},{"name":"Department of Psychiatry, University of Alabama at Birmingham Medical Center , Birmingham, AL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley G","family":"Burk","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Department of Psychiatry, University of Alabama at Birmingham Medical Center , Birmingham, AL"},{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine , Birmingham, AL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"issue":"1","key":"2024112205524131600_CIT0001","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2165\/00002018-199819010-00005","article-title":"Managing antipsychotic-induced acute and tardive dystonia","volume":"19","author":"Raja","year":"1998","journal-title":"Drug Saf"},{"issue":"suppl 1","key":"2024112205524131600_CIT0002","doi-asserted-by":"publisher","first-page":"229","DOI":"10.18865\/ed.30.S1.229","article-title":"Exploring biologic predictors response disparities to atypical antipsychotics among blacks: a quasi-systematic review","volume":"30","author":"Jerome","year":"2020","journal-title":"Ethn Dis"},{"issue":"4","key":"2024112205524131600_CIT0003","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/JCP.0000000000001061","article-title":"Characteristics of patients experiencing extrapyramidal symptoms or other movement disorders related to dopamine receptor blocking agent therapy","volume":"39","author":"Musco","year":"2019","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"2024112205524131600_CIT0004","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/10673220600748486","article-title":"Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome","volume":"14","author":"Shirzadi","year":"2006","journal-title":"Harv Rev Psychiatry"},{"issue":"7210","key":"2024112205524131600_CIT0005","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/bmj.319.7210.623","article-title":"Acute dystonia induced by drug treatment","volume":"319","author":"van Harten","year":"1999","journal-title":"BMJ"},{"issue":"1","key":"2024112205524131600_CIT0006","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881120944156","article-title":"Neurobiological mechanisms associated with antipsychotic drug-induced dystonia","volume":"35","author":"Loonen","year":"2021","journal-title":"J Psychopharmacol"},{"issue":"1","key":"2024112205524131600_CIT0007","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"issue":"10202","key":"2024112205524131600_CIT0008","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"2024112205524131600_CIT0009","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00004714-198706000-00008","article-title":"Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions","volume":"7","author":"Boyer","year":"1987","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"2024112205524131600_CIT0010","doi-asserted-by":"publisher","first-page":"20","DOI":"10.12788\/cp.0229","article-title":"Do no harm: benztropine revisited","volume":"21","author":"Soka","year":"2022","journal-title":"Current Psychiatry"},{"issue":"8","key":"2024112205524131600_CIT0011","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1176\/ajp.145.8.993","article-title":"Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia","volume":"145","author":"Arana","year":"1988","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2024112205524131600_CIT0012","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/00004850-199300810-00003","article-title":"Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis","volume":"8","author":"Spina","year":"1993","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"2024112205524131600_CIT0013","first-page":"36","article-title":"Assesment of risk factors for tardive dyskinesia","volume":"50","author":"Vardar","year":"2020","journal-title":"Psychopharmacol Bull"},{"issue":"9","key":"2024112205524131600_CIT0014","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"7","key":"2024112205524131600_CIT0015","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers criteria for potentially inappropriate medication use in older adults","volume":"71","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"2024112205524131600_CIT0016","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"3","key":"2024112205524131600_CIT0017","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40266-018-00630-z","article-title":"Drugs contributing to anticholinergic burden and risk of fall or fall-related injury among older adults with mild cognitive impairment, dementia and multiple chronic conditions: a retrospective cohort study","volume":"36","author":"Green","year":"2019","journal-title":"Drugs Aging"},{"issue":"4","key":"2024112205524131600_CIT0018","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.jds.2023.01.019","article-title":"Potential association of anticholinergic medication intake and caries experience in young adults with xerostomia","volume":"18","author":"Kakkar","year":"2023","journal-title":"J Dent Sci"},{"issue":"4","key":"2024112205524131600_CIT0019","first-page":"36","article-title":"Differential diagnosis of urinary incontinence","volume":"33","author":"Brocklehurst","year":"1978","journal-title":"Geriatrics"},{"issue":"1","key":"2024112205524131600_CIT0020","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/pcn.12088","article-title":"Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function","volume":"68","author":"Ogino","year":"2014","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"2024112205524131600_CIT0021","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archgenpsychiatry.2009.175","article-title":"National trends in psychotropic medication polypharmacy in office-based psychiatry","volume":"67","author":"Mojtabai","year":"2010","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"2024112205524131600_CIT0022","doi-asserted-by":"publisher","first-page":"12","DOI":"10.9740\/mhc.2021.01.012","article-title":"The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection","volume":"11","author":"Stump","year":"2021","journal-title":"Ment Health Clin"},{"issue":"6","key":"2024112205524131600_CIT0023","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/jnc.15244","article-title":"Tardive neurotoxicity of anticholinergic drugs: a review","volume":"158","author":"Marzoughi","year":"2021","journal-title":"J Neurochem"},{"key":"2024112205524131600_CIT0024","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fnbeh.2012.00024","article-title":"Cholinergic modulation of cognitive processing: insights drawn from computational models","volume":"6","author":"Newman","year":"2012","journal-title":"Front Behav Neurosci"},{"issue":"2","key":"2024112205524131600_CIT0025","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40120-018-0105-0","article-title":"Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia\u2014key differences in pathophysiology and clinical management","volume":"7","author":"Ward","year":"2018","journal-title":"Neurol Ther"},{"issue":"5","key":"2024112205524131600_CIT0026","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2174\/1570159X14666161208153644","article-title":"Revisiting antipsychotic-induced akathisia: current issues and prospective challenges","volume":"15","author":"Salem","year":"2017","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"2024112205524131600_CIT0027","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1755-5949.2010.00142.x","article-title":"Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders","volume":"16","author":"Lester","year":"2010","journal-title":"CNS Neurosci Ther"},{"issue":"10","key":"2024112205524131600_CIT0028","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/j.sapharm.2020.12.010","article-title":"Deprescribing anticholinergic medication in the community mental health setting: a quality improvement initiative","volume":"17","author":"Gannon","year":"2021","journal-title":"Res Social Adm Pharm"},{"issue":"6","key":"2024112205524131600_CIT0029","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/2045125314553611","article-title":"Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia","volume":"4","author":"Desmarais","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"issue":"9","key":"2024112205524131600_CIT0030","doi-asserted-by":"publisher","first-page":"e1270","DOI":"10.4088\/JCP.16m11269","article-title":"Reducing anticholinergic medication burden in patients with psychotic or bipolar disorders","volume":"78","author":"Lupu","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"2024112205524131600_CIT0031","volume-title":"The Improvement Guide: A Practical Approach to Enhancing Organizational Performance","author":"Langley","year":"2009","edition":"2"},{"issue":"2","key":"2024112205524131600_CIT0032","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1600-0447.2005.00589.x","article-title":"Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy","volume":"113","author":"Carnahan","year":"2006","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"2024112205524131600_CIT0033","doi-asserted-by":"publisher","first-page":"22m03472","DOI":"10.4088\/PCC.22m03472","article-title":"Investigating real-world benztropine usage patterns in movement disorders: claims analysis and health care provider survey results","volume":"25","author":"Chepke","year":"2023","journal-title":"Prim Care Companion CNS Disord"},{"issue":"3","key":"2024112205524131600_CIT0034","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.jagp.2022.12.176","article-title":"Use of anticholinergics for drug-induced movement disorders with implications for elderly patients","volume":"31","author":"Chepke","year":"2023","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"2024112205524131600_CIT0035","first-page":"143","article-title":"Withdrawal-emergent dyskinesia related to benztropine: a case report","volume":"122","author":"Thalner","year":"2023","journal-title":"WMJ"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae196\/58689384\/zxae196.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/23\/e742\/60780045\/zxae196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/23\/e742\/60780045\/zxae196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T05:56:14Z","timestamp":1732254974000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/81\/23\/e742\/7715867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":35,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,7,17]]},"published-print":{"date-parts":[[2024,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae196","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"type":"print","value":"1079-2082"},{"type":"electronic","value":"1535-2900"}],"subject":[],"published-other":{"date-parts":[[2024,12,1]]},"published":{"date-parts":[[2024,7,17]]}}}